Please assess the completion status of the following clinical trial:

Trial Title: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)~* BMI 27-30 with a controlled obesity-related co-morbidity; or BMI ≥ 30 and \<50;~* Available for the duration of the treatment and follow-up (20 months);~* Read, comprehend, and write English at a sufficient level to complete study-related materials;~* Able to travel to study location (New Haven, CT) for weekly visits.~Exclusion Criteria:~* Currently taking anti-depressant medications;~* Currently taking opioid pain medications or drugs;~* Currently taking medications that influence eating/weight;~* History of seizures;~* Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality);~* Past or current anorexia nervosa, bulimia nervosa;~* Pregnant or breastfeeding;~* Medical status judged by study physician as contraindication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BWL + NB medication (Type: EXPERIMENTAL): Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
- BWL + Placebo (Type: EXPERIMENTAL): Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
- NB medication (Type: EXPERIMENTAL): Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.

Based on this trial design, predict the completion outcome and termination type (if applicable).